PMLiVE6h
MHRA approves CSL’s Andembry to treat angioedema attacks in HAE patients
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved CSL’s Andembry (garadacimab) to prevent ...
PMLiVE6h
AstraZeneca’s Imfinzi recommended by CHMP to treat small cell lung cancer
The Committee for Medicinal Products for Human Use (CHMP) has recommended that the immunotherapy be approved to treat adults ...
PMLiVE6h
J&J’s subcutaneous Rybrevant receives positive CHMP opinion for advanced lung cancer
The Committee for Medicinal Products for Human Use (CHMP) has recommended that the subcutaneous (SC) formulation be approved ...
PMLiVE8h
Optimising business partnerships for success and sustainability
Challenging times can put a strain on any relationship, making it harder to keep everything working in harmony. The ...
PMLiVE7h
Why events should be part of your 2025 growth strategy
Over eighty per cent of businesses rank in-person events as their most impactful marketing channel. In fact, 48 per cent of ...
PMLiVE3d
ICR researchers uncover new method for predicting bowel cancer risk in IBD patients
Scientists from the Institute of Cancer Research (ICR) have found a new method for predicting bowel cancer risk in ...
PMLiVE3d
Amgen’s Blincyto granted EC approval for new acute lymphoblastic leukaemia indication
Amgen’s Blincyto (blinatumomab) has been approved by the European Commission (EC) to treat certain acute lymphoblastic ...
PMLiVE5d
Novo Nordisk’s Ozempic granted FDA approval in chronic kidney disease
Novo Nordisk’s Ozempic (semaglutide) has been approved by the US Food and Drug Administration (FDA) to reduce the risk of ...
PMLiVE6d
The silent treatment – researching gene silencing for Alzheimer’s, Parkinson’s and motor neurone disease
In trials at University College London Hospitals (UCLH), an ASO is being used to target the mutated gene that results in the ...
PMLiVE12d
AstraZeneca receives NICE recommendations for lung cancer drugs Tagrisso and Imfinzi
AstraZeneca (AZ) has received two separate recommendations from the National Institute for Health and Care Excellence (NICE) ...
PMLiVE3d
NICE approves Vertex’s Casgevy one-time gene therapy for sickle cell disease
The National Institute for Health and Care Excellence (NICE) has approved Vertex Pharmaceuticals’ Casgevy (exagamglogene ...
PMLiVE5d
Bayer UK launches digital educational hub to improve menopause support
Bayer Consumer Health has launched a digital educational resource to support perimenopausal or menopausal patients in the UK.